Atea Pharmaceuticals, Inc.
- AVIR
- NASDAQ
- Biotechnology
- Antiviral Drug Development
- Infectious Disease Biotech
$4.39
Today +1.62%Quote Oct 19, 2026, 08:00 PM UTC
−17.87%over the last month
Max drawdown −23.4%From 1-month high −23.4%3 months −9.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Atea Pharmaceuticals
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
55
Founded
2012
Market value
$352.1M
Quote Oct 19
Analyst target
$7.00
+59.5% from here
Floor
$3.80
13.4% below price
Resistance
$4.56
3.8% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about AVIRPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free